Chemical Composition, In vitro and In silico Evaluation of Essential Oil from Ocimum tenuiflorum and Coriandrum sativum Linn for Lung Cancer


如何引用文章

全文:

详细

Background:Medicinal plants play an essential role in everyday life; plants highly contain therapeutic phytoconstituents commonly used to treat various diseases. This paper discusses the Chemical composition, In vitro antiproliferative activity and In silico study of essential oil extracted from Ocimum tenuiflorum (family Lamiaceae) and Coriandrum sativum (family Apiaceae).

Objective:In present study GC-MS was used to identify the chemical constituents from O. tenuiflorum and C. sativum. In vitro antiproliferative activity was performed on A549 cancer cell lines. In silico study was performed by Schrodinger’s maestro software to identify chemical constituents in both plants as potential EGFR inhibitors for the treatment of lung cancer

Methods:The essential oil was extracted by hydro distillation from aerial parts of O. tenuiflorum and C. sativum. The volatile oil sample was analyzed by (GC-MS) Gas Chromatography- Mass Spectrometry. Different chemical constituents were identified based on the retention index and compared with the NIST library. The oil samples from O. tenuiflorum and C. sativum was also evaluated for antiproliferative activity against human lung cancer A549 cell lines. In silico study was performed by Schrodinger maestro software against EGFR (PDB ID 5HG8).

Resuls:O. tenuiflorum essential oil contains Eugenol (42.90%), 2-β-Elemene (25.98%), β- Caryophyllene (19.12%) are the major constituents. On the other side, C. sativum contains nnonadecanol- 1 (16.37%), decanal (12.37%), dodecanal (12.27%), 2-Dodecanal (9.67%), Phytol (8.81%) as the major constituents. Both the oils have shown in vitro antiproliferative activity against human lung cancer cell lines A549 having IC50 values of 38.281 µg/ml (O. tenuiflorum) and 74.536 µg/ml (C. sativum). Molecular interactions of constituents hydro distilled from two oils was analysed by schrodinger maestro software against EGFR (PDB ID 5HG8).

Conclusion:The oil sample extracted from O. tenuiflorum showed more antiproliferative activity than C. sativum. In silico study showed that two chemical constituents, namely di-isobutyl phthalate (-7.542 kcal/mol) and dibutyl phthalate (-7.181 kcal/mol) from O. tenuiflorum and one diethyl phthalate (-7.224 kcal/mol) from C. sativum having more docking score than standard Osimertinib which indicates the effectiveness of oils for lung cancer.

作者简介

Bhim Singh

Natural Product Chemistry Laboratory, Department of Pharmaceutical Sciences & Natural Products, Central University of Punjab

Email: info@benthamscience.net

Kumari Prajapati

Molecular Signaling and Drug Discovery Laboratory, Department of Biochemistry,, Central University of Punjab

Email: info@benthamscience.net

Amit Kumar

Natural Product Chemistry Laboratory, Department of Pharmaceutical Sciences & Natural Products, Central University of Punjab

Email: info@benthamscience.net

Shivam Patel

Natural Product Chemistry Laboratory, Department of Pharmaceutical Sciences & Natural Products, Central University of Punjab

Email: info@benthamscience.net

Shashank Kumar

Molecular Signaling and Drug Discovery Laboratory, Department of Biochemistry,, Central University of Punjab

Email: info@benthamscience.net

Vikas Jaitak

Natural Product Chemistry Laboratory, Department of Pharmaceutical Sciences & Natural Products, Central University of Punjab

编辑信件的主要联系方式.
Email: info@benthamscience.net

参考

  1. Xia, C.; Dong, X.; Li, H.; Cao, M.; Sun, D.; He, S.; Yang, F.; Yan, X.; Zhang, S.; Li, N.; Chen, W. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin. Med. J., 2022, 135(5), 584-590. doi: 10.1097/CM9.0000000000002108 PMID: 35143424
  2. Deo, S.V.S.; Sharma, J.; Kumar, S. GLOBOCAN 2020 report on global cancer burden: Challenges and opportunities for surgical oncologists. Ann. Surg. Oncol., 2022, 29(11), 6497-6500. doi: 10.1245/s10434-022-12151-6 PMID: 35838905
  3. Pradhan, K.S.; Chawla, P.; Tiwari, R. HRDEL: High ranking deep ensemble learning-based lung cancer diagnosis model. Expert Syst. Appl., 2023, 213, 118956. doi: 10.1016/j.eswa.2022.118956
  4. Sharma, P.; Mehta, M.; Dhanjal, D.S.; Kaur, S.; Gupta, G.; Singh, H.; Thangavelu, L.; Rajeshkumar, S.; Tambuwala, M.; Bakshi, H.A.; Chellappan, D.K.; Dua, K.; Satija, S. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. Chem. Biol. Interact., 2019, 309, 108720. doi: 10.1016/j.cbi.2019.06.033 PMID: 31226287
  5. Chen, L.; Fu, W.; Zheng, L.; Liu, Z.; Liang, G. Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer: Miniperspective. J. Med. Chem., 2018, 61(10), 4290-4300. doi: 10.1021/acs.jmedchem.7b01310 PMID: 29136465
  6. Tian, X.; Gu, T.; Lee, M.H.; Dong, Z. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. Biochim. Biophys. Acta Rev. Cancer, 2022, 1877(1), 188645. doi: 10.1016/j.bbcan.2021.188645 PMID: 34793897
  7. Cao, S.Y.; Li, Y.; Meng, X.; Zhao, C.N.; Li, S.; Gan, R.Y.; Li, H.B. Dietary natural products and lung cancer: Effects and mechanisms of action. J. Funct. Foods, 2019, 52, 316-331. doi: 10.1016/j.jff.2018.11.004
  8. Hoy, H.; Lynch, T.; Beck, M. Surgical treatment of lung cancer. Crit. Care Nurs. Clin. North Am., 2019, 31(3), 303-313. PMID: 31351552
  9. Eltayeb, K.; La Monica, S.; Tiseo, M.; Alfieri, R.; Fumarola, C. Reprogramming of lipid metabolism in lung cancer: An overview with focus on EGFR-Mutated non-small cell lung cancer. Cells, 2022, 11(3), 413. doi: 10.3390/cells11030413 PMID: 35159223
  10. Leonetti, A.; Sharma, S.; Minari, R.; Perego, P.; Giovannetti, E.; Tiseo, M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer, 2019, 121(9), 725-737. doi: 10.1038/s41416-019-0573-8 PMID: 31564718
  11. Skribek, M.; Rounis, K.; Tsakonas, G.; Ekman, S. Complications following novel therapies for non‐small cell lung cancer. J. Intern. Med., 2022, 291(6), 732-754. doi: 10.1111/joim.13445 PMID: 35032058
  12. Alam, M.; Alam, S.; Shamsi, A.; Adnan, M.; Elasbali, A.M.; Al-Soud, W.A.; Alreshidi, M.; Hawsawi, Y.M.; Tippana, A.; Pasupuleti, V.R.; Hassan, M.I. Bax/Bcl-2 cascade is regulated by the EGFR pathway: Therapeutic targeting of non-small cell lung cancer. Front. Oncol., 2022, 12, 869672. doi: 10.3389/fonc.2022.869672 PMID: 35402265
  13. Sharma, S.; Kumar, K.; Thakur, N.; Chauhan, S.; Chauhan, M.S. Eco-friendly Ocimum tenuiƒlorum green route synthesis of CuO nanoparticles: Characterizations on photocatalytic and antibacterial activities. J. Environ. Chem. Eng., 2021, 9(4), 105395. doi: 10.1016/j.jece.2021.105395
  14. Piras, A.; Gonçalves, M.J.; Alves, J.; Falconieri, D.; Porcedda, S.; Maxia, A.; Salgueiro, L. Ocimum tenuiƒlorum L. and Ocimum basilicum L., two spices of Lamiaceae family with bioactive essential oils. Ind. Crops Prod., 2018, 113, 89-97. doi: 10.1016/j.indcrop.2018.01.024
  15. Chandra, M.; Kushwaha, S.; Mishra, B.; Sangwan, N. Molecular and structural insights for the regulation of terpenoids in Ocimum basilicum and Ocimum tenuiƒlorum. Plant Growth Regul., 2022, 97(1), 61-75. doi: 10.1007/s10725-022-00796-y
  16. Prakash, P.; Gupta, N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: A short review. Indian J. Physiol. Pharmacol., 2005, 49(2), 125-131. PMID: 16170979
  17. Sampath Kumar, K.P.; Bhowmik, D.; Biswajit, C.; Tripathi, K.K. Traditional indian herbal plants tulsi and its medicinal importance. J. Pharmacogn. Phytochem., 2010, 2(2), 93-101.
  18. M, S.; Kr, S.; B, S.; G, V.; S, R.; K, S.; K, M. Ocimum sanctum: A review on the pharmacological properties. Int. J. Basic Clin. Pharmacol., 2016, 5(3), 558-565. doi: 10.18203/2319-2003.ijbcp20161491
  19. Al-Khayri, J.M.; Banadka, A.; Nandhini, M.; Nagella, P.; Al-Mssallem, M.Q.; Alessa, F.M. Essential Oil from Coriandrum sativum: A review on its phytochemistry and biological activity. Molecules, 2023, 28(2), 696. doi: 10.3390/molecules28020696 PMID: 36677754
  20. Kačániová, M.; Galovičová, L.; Ivanišová, E.; Vukovic, N.L.; Štefániková, J.; Valková, V.; Borotová, P.; Žiarovská, J.; Terentjeva, M.; Felšöciová, S.; Tvrdá, E. Antioxidant, antimicrobial and antibiofilm activity of coriander (Coriandrum sativum L.) essential oil for its application in foods. Foods, 2020, 9(3), 282. doi: 10.3390/foods9030282 PMID: 32143314
  21. Ahmed, E.H.; Abadi, R.S.; Mohammed, A.M. Phytochemical screening, chemical composition and antioxidant activity of seeds essential oil of Coriandrum sativum L. from the Sudan. Int. J. Herb. Med., 2018, 6(1), 1-4.
  22. Zeb, A. Coriander (Coriandrum sativum) Oils. In: Essential Oils in Food Preservation, Flavor and Safety; Preedy, V.R., Ed.; Academic Press: San Diego, 2016; pp. 359-364. doi: 10.1016/B978-0-12-416641-7.00040-7
  23. Pavlić, B.; Vidović, S.; Vladić, J.; Radosavljević, R.; Zeković, Z. Isolation of coriander (Coriandrum sativum L.) essential oil by green extractions versus traditional techniques. J. Supercrit. Fluids, 2015, 99, 23-28. doi: 10.1016/j.supflu.2015.01.029
  24. Sourmaghi, M.H.S.; Kiaee, G.; Golfakhrabadi, F.; Jamalifar, H.; Khanavi, M. Comparison of essential oil composition and antimicrobial activity of Coriandrum sativum L. extracted by hydrodistillation and microwave-assisted hydrodistillation. J. Food Sci. Technol., 2015, 52(4), 2452-2457. doi: 10.1007/s13197-014-1286-x PMID: 25829632
  25. Salem, M.A.; Manaa, E.G.; Osama, N.; Aborehab, N.M.; Ragab, M.F.; Haggag, Y.A.; Ibrahim, M.T.; Hamdan, D.I. Coriander (Coriandrum sativum L.) essential oil and oil-loaded nano-formulations as an anti-aging potentiality via TGFβ/SMAD pathway. Sci. Rep., 2022, 12(1), 6578. doi: 10.1038/s41598-022-10494-4 PMID: 35449437
  26. Saini, N.; Grewal, A.S.; Lather, V.; Gahlawat, S.K. Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions. Chem. Biol. Interact., 2022, 358, 109901. doi: 10.1016/j.cbi.2022.109901 PMID: 35341731
  27. Hasan, M.R.; Alotaibi, B.S.; Althafar, Z.M.; Mujamammi, A.H.; Jameela, J. An update on the therapeutic anticancer potential of ocimum sanctum L.: "Elixir of life". Molecules, 2023, 28(3), 1193. doi: 10.3390/molecules28031193 PMID: 36770859
  28. Boonyanugomol, W.; Rukseree, K.; Prapatpong, P.; Reamtong, O.; Baik, S.-C.; Jung, M.; Shin, M.-K.; Kang, H.-L.; Lee, W.-K. An in vitro anti-cancer activity of ocimum tenuiƒlorum essential oil by inducing apoptosis in human gastric cancer cell line. Medicina, 2021, 57(8), 784. doi: 10.3390/medicina57080784
  29. Kumar, A.; Yadav, P.; Navik, U.; Jaitak, V. Chemical composition, in vitro and in silico evaluation of essential oil from Eucalyptus tereticornis leaves for lung cancer. Nat. Prod. Res., 2023, 37(10), 1656-1661.
  30. Kumar, A.; Gupta, K.B.; Dhiman, M.; Arora, S.; Jaitak, V. New pentacyclic triterpene from Potentilla atrosanguinea Lodd. as anticancer agent for breast cancer targeting estrogen receptor- α. Nat. Prod. Res., 2022, 36(17), 4352-4357. doi: 10.1080/14786419.2021.1986495 PMID: 34606404
  31. Kumar, A.; Kalra, S.; Jangid, K.; Jaitak, V. Flavonoids as P-glycoprotein inhibitors for multidrug resistance in cancer: An in-silico approach. J. Biomol. Struct. Dyn., 2023, 41(16), 7627-7639. doi: 10.1080/07391102.2022.2123390 PMID: 36120941
  32. Aravind, AP.; Kumar, A.; Jangid, K.; Vinod, K.; Vikas, J. Structure-Structure for the identification of terpenoids as potential DPP-4 inhibitors. Curr. Comput. Aided. Drug Des., 2023.
  33. Justus, B.; Kanunfre, C.C.; Budel, J.M.; de Faria, M.F.; Raman, V.; de Paula, J.P.; Farago, P.V. New insights into the mechanisms of French lavender essential oil on non-small-cell lung cancer cell growth. Ind. Crops Prod., 2019, 136, 28-36. doi: 10.1016/j.indcrop.2019.04.051
  34. Sharma, M.; Grewal, K.; Jandrotia, R.; Batish, D.R.; Singh, H.P.; Kohli, R.K. Essential oils as anticancer agents: Potential role in malignancies, drug delivery mechanisms, and immune system enhancement. Biomed. Pharmacother., 2022, 146, 112514. doi: 10.1016/j.biopha.2021.112514 PMID: 34963087
  35. Odogwu, L.; Mathieu, L.; Goldberg, K.B.; Blumenthal, G.M.; Larkins, E.; Fiero, M.H.; Rodriguez, L.; Bijwaard, K.; Lee, E.Y.; Philip, R.; Fan, I.; Donoghue, M.; Keegan, P.; McKee, A.; Pazdur, R. FDA benefit-risk assessment of osimertinib for the treatment of metastatic non-small cell lung cancer harboring epidermal growth factor receptor T790M mutation. Oncologist, 2018, 23(3), 353-359. doi: 10.1634/theoncologist.2017-0425 PMID: 29242281
  36. QikProp. 2022. Available from: https://www.schrodinger.com/products/qikprop

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bentham Science Publishers, 2024